tiprankstipranks
Trending News
More News >

Ginkgo Bioworks Announces CFO Transition

Story Highlights
  • Ginkgo Bioworks announced CFO Mark Dmytruk’s resignation effective May 30, 2025.
  • Steven Coen will succeed Dmytruk as CFO, focusing on financial strategies and cost targets.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Ginkgo Bioworks Announces CFO Transition

Confident Investing Starts Here:

An announcement from Ginkgo Bioworks Holdings ( (DNA) ) is now available.

On May 21, 2025, Ginkgo Bioworks announced the resignation of its Chief Financial Officer, Mark Dmytruk, effective May 30, 2025, as he transitions to another organization. Steven Coen, the current Chief Accounting Officer, will assume the role of CFO, bringing over 30 years of experience in public accounting and corporate finance. Coen’s appointment is expected to provide continuity and build upon the financial strategies laid out by Dmytruk, with a focus on achieving cost reduction targets and reaching Adjusted EBITDA breakeven by the end of 2026.

The most recent analyst rating on (DNA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.

Spark’s Take on DNA Stock

According to Spark, TipRanks’ AI Analyst, DNA is a Neutral.

Ginkgo Bioworks Holdings shows potential with strategic cost reductions and revenue growth, but faces substantial financial challenges, including net losses and negative cash flows. Technical indicators suggest short-term momentum, yet valuation remains unattractive due to unprofitability. The earnings call highlighted progress but also acknowledged significant hurdles, resulting in a cautiously optimistic outlook. Overall, while there are promising developments, the risks and challenges weigh heavily on the stock.

To see Spark’s full report on DNA stock, click here.

More about Ginkgo Bioworks Holdings

Ginkgo Bioworks is a leading platform for cell programming and biosecurity, offering end-to-end services across various markets including food, agriculture, pharmaceuticals, and specialty chemicals. The company is focused on building infrastructure and technologies to address biological threats globally.

Average Trading Volume: 1,434,563

Technical Sentiment Signal: Sell

Current Market Cap: $473.5M

For detailed information about DNA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App